Catalyst MedTech, a national leader in nuclear medicine and molecular imaging solutions, has announced it will serve as the exclusive U.S. distributor of CareMiBrain™, an ultra-high resolution dedicated brain PET system developed by MindView / OncoVision. This milestone marks a powerful collaboration between Catalyst MedTech and OncoVision, reinforcing our shared commitment to expanding access to advanced neurologic imaging across the U.S.
Designed specifically for neurologic imaging and research, CareMiBrain™ delivers ultra-high resolution, high sensitivity, and superior patient comfort—all in a compact footprint that integrates seamlessly into imaging departments, outpatient centers, or as a standalone solution in private practices. This next-generation system opens a new window into the human brain, advancing our ability to understand cognition, disease progression, and even potential pathways to recovery. The complete solution will be publicly showcased for the first time in the U.S. in Catalyst MedTech’s Booth (#701) during the SNMMI 2025 Annual Meeting in New Orleans.
“This is more than a distribution agreement,” said Martin Shirley, President and CEO of Catalyst MedTech. “This is a defining moment. As part of Catalyst’s U.S. market strategy, we’ve paired CareMiBrain™ with Syntermed’s NeuroQ4™, the industry’s leading brain analysis software. NeuroQ4™ provides advanced analysis for neurologic PET images for Epilepsy, Oncology and Amyloid Analysis (including centiloids). Catalyst MedTech is delivering the complete neurologic PET solution U.S. physicians have been waiting for. As an extension of our company’s purpose, our legacy will now include this complete Neurologic PET solution.
Key Advantages of the Ultra-High Resolution Dedicated Brain PET System:
- <1.6 mm spatial resolution for advanced neurological diagnostics
- Proven performance in >600 patients, including amyloid and tau imaging
- Ergonomic, reclining patient design with ultra-fast acquisition times
- Flexible power (115–240V), low heat generation, small room requirements (~8’x13’)
- Fully integrated acquisition, quantification, and reconstruction software
- Optional integration with SynterMed NeuroQ4™ for quantitative brain analysis
NeuroQ4™ Enhances the Solution With:
- The leading brain imaging analysis software
- FDG-PET for Oncology and Epilepsy
- Amyloid Analysis
- Serial Comparison to Monitor Disease Progression
- Clear Picture of Dementia with a Major Impact on Therapy